Charles River Laboratories International and The Francis Crick Institute (Crick) have entered a new collaboration in Antibody-Drug Conjugate (ADC) drug discovery and development, aiming to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and characterization—bringing promising ADC candidates to the clinic faster and more efficiently.  This end-to-end approach—spanning antibody discove...